REGN5069
R5069-OA-1849
Phase 2 small_molecule terminated
Quick answer
REGN5069 for Osteoarthritis of the Knee is a Phase 2 program (small_molecule) at REGENERON PHARMACEUTICALS, INC. with 1 ClinicalTrials.gov record(s).
Program details
- Company
- REGENERON PHARMACEUTICALS, INC.
- Indication
- Osteoarthritis of the Knee
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- terminated